Barinthus Biotherapeutics Q2 EPS $(0.43) Misses $(0.41) Estimate
Portfolio Pulse from Benzinga Newsdesk
Barinthus Biotherapeutics (NASDAQ:BRNS) reported a Q2 EPS loss of $(0.43), missing the analyst estimate of $(0.41) by 4.88%. This is an improvement from the $(0.62) loss per share in the same period last year.
August 08, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barinthus Biotherapeutics reported a Q2 EPS loss of $(0.43), missing the analyst estimate of $(0.41) by 4.88%. Despite the miss, the loss is an improvement from the $(0.62) per share loss in the same period last year.
The EPS miss is likely to have a negative short-term impact on the stock price as it fell short of analyst expectations. However, the improvement from last year's loss may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100